POINT RICHMOND, Calif., April 10, 2013 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Thomas J. Dietz, Ph.D., Chairman and CEO of Waypoint Holdings, LLC, a financial holdings and services company, has joined the board of Transcept Pharmaceuticals as an independent director effective April 10, 2013. Dr. Dietz has more than 20 years of experience supporting the biopharma industry and the institutional investment community. Prior to his current role as Chairman and CEO of Waypoint Holdings, Dr. Dietz was co-CEO and then CEO and a Director of Pacific Growth Equities, LLC, a San Francisco-based investment bank and institutional brokerage firm from 2004 to 2009, when the firm was acquired by Wedbush Securities. Dr. Dietz served as head of the investment banking division at Webush until November 2010. Prior to becoming CEO at Pacific Growth, Dr. Dietz served as the firm's Director of Equities Research and was an award-winning biotechnology and biopharmaceutical analyst. Dr. Dietz joined Pacific Growth in 1993. Previously, he was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center. Dr. Dietz is a member of several national societies and currently serves as Chairman of Galleon Pharmaceuticals, Inc. and Director of Glialogix, Inc. as well as on the boards of trustees of several non-profit organizations, including the West Bay Region board of the Sutter Health System that includes California Pacific Medical Center, San Francisco. Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University, St. Louis, and was a National Science Foundation Post-Doctoral Fellow. "The addition of Tom Dietz further enhances the Board's already strong pharmaceutical industry expertise," stated Glenn Oclassen, President and Chief Executive Officer. "Tom brings a track-record of success and deep industry knowledge, and his viewpoint and advice will be important as we move through the next stage of our corporate development." "Transcept Pharmaceuticals has a unique asset in Intermezzo, an experienced management team and a strong balance sheet," stated Dr. Dietz. "I look forward to working with the Transcept board and team to capitalize upon these assets and to create shareholder value."